WO1999035165A1 - Proteines secretees et polynucleotides les codant - Google Patents
Proteines secretees et polynucleotides les codant Download PDFInfo
- Publication number
- WO1999035165A1 WO1999035165A1 PCT/US1999/000338 US9900338W WO9935165A1 WO 1999035165 A1 WO1999035165 A1 WO 1999035165A1 US 9900338 W US9900338 W US 9900338W WO 9935165 A1 WO9935165 A1 WO 9935165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nucleotide
- polynucleotide
- sequence
- nucleotide sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:4.
- the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:4;
- the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO:8.
- the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
- the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 64 to amino acid 73 of SEQ
- the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 72 to amino acid 81 of SEQ ID NO:18.
- the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 374 to nucleotide 415, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 374 to nucleotide 415, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 374 to nucleotide 415.
- nm214_3 A polynucleotide of the present invention has been identified as clone "nm214_3".
- nm214_3 was isolated from a human adult blood (erythroleukemia TF-1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
- nm214_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nm214_3 protein").
- the oligonucleotide should preferably be labeled with ⁇ - 32 P ATP (specific activity 6000
- MLR Mixed lymphocyte reaction
- Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells.
- a protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
- Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
- a protein of the invention may also exhibit hemostatic or thrombolytic activity.
- compositions used to practice the method of the present invention should contain about 0.01 ⁇ g to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight.
- the amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
- proteins of the invention may be combined with other agents beneficial to the treatment of the bone and /or cartilage defect, wound, or tissue in question.
- Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000527560A JP2002500037A (ja) | 1998-01-08 | 1999-01-07 | 分泌蛋白およびそれらをコードするポリヌクレオチド |
CA002316775A CA2316775A1 (fr) | 1998-01-08 | 1999-01-07 | Proteines secretees et polynucleotides les codant |
AU20296/99A AU2029699A (en) | 1998-01-08 | 1999-01-07 | Secreted proteins and polynucleotides encoding them |
EP99900791A EP1044220A1 (fr) | 1998-01-08 | 1999-01-07 | Proteines secretees et polynucleotides les codant |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7075598P | 1998-01-08 | 1998-01-08 | |
US60/070,755 | 1998-01-08 | ||
US22558599A | 1999-01-06 | 1999-01-06 | |
US09/225,585 | 1999-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999035165A1 true WO1999035165A1 (fr) | 1999-07-15 |
Family
ID=26751469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000338 WO1999035165A1 (fr) | 1998-01-08 | 1999-01-07 | Proteines secretees et polynucleotides les codant |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1044220A1 (fr) |
JP (1) | JP2002500037A (fr) |
AU (1) | AU2029699A (fr) |
CA (1) | CA2316775A1 (fr) |
WO (1) | WO1999035165A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012708A2 (fr) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Nouveaux pro-polypeptides et sequences correspondantes |
-
1999
- 1999-01-07 JP JP2000527560A patent/JP2002500037A/ja not_active Withdrawn
- 1999-01-07 CA CA002316775A patent/CA2316775A1/fr not_active Abandoned
- 1999-01-07 AU AU20296/99A patent/AU2029699A/en not_active Abandoned
- 1999-01-07 EP EP99900791A patent/EP1044220A1/fr not_active Withdrawn
- 1999-01-07 WO PCT/US1999/000338 patent/WO1999035165A1/fr not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
AYALA F. J., ET AL.: "CHOMOSOMAL MUTATIONS.", MODERN GENETICS, XX, XX, vol. 575., no. 01., 1 January 1984 (1984-01-01), XX, pages 694., XP002920788 * |
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920785, Database accession no. H12643 * |
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920786, Database accession no. AA230132 * |
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920787, Database accession no. AC005703 * |
JACOBS K A, ET AL.: "A GENETIC SELECTION FOR ISOLATING CDNAS ENCODING SECRETED PROTEINS", GENE., ELSEVIER, AMSTERDAM., NL, vol. 198, 1 October 1997 (1997-10-01), NL, pages 289 - 296, XP002045919, ISSN: 0378-1119, DOI: 10.1016/S0378-1119(97)00330-2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012708A2 (fr) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Nouveaux pro-polypeptides et sequences correspondantes |
WO2000012708A3 (fr) * | 1998-09-01 | 2001-10-04 | Genentech Inc | Nouveaux pro-polypeptides et sequences correspondantes |
Also Published As
Publication number | Publication date |
---|---|
EP1044220A1 (fr) | 2000-10-18 |
CA2316775A1 (fr) | 1999-07-15 |
JP2002500037A (ja) | 2002-01-08 |
AU2029699A (en) | 1999-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000055375A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999042470A1 (fr) | Proteines secretees et polynucleotides codant lesdites proteines | |
EP1068307A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1075487A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1012261A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1053252A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999046287A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999026961A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO2000050592A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999035252A2 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999018127A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1032594A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999053045A1 (fr) | Proteines secretees et polynucleotides codant pour celles-ci | |
EP1064302A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999037674A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999038959A1 (fr) | Proteines secretees et polynucleotides codant pour elles | |
EP1044220A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1037970A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999024469A1 (fr) | Proteines secretees et polynucleotides les codant | |
EP1012263A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO1999051732A1 (fr) | Proteines secretees et polynucleotides codant pour ces proteines | |
WO2001075133A1 (fr) | Proteines secretees et polynucleotides codant pour celles-ci | |
EP1047772A1 (fr) | Proteines secretees et polynucleotides les codant | |
WO2000063692A1 (fr) | Proteines secretees et polynucleotides codant ces dernieres | |
WO1999028335A1 (fr) | Proteines secretees et polynucleotides les codant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2316775 Country of ref document: CA Ref country code: CA Ref document number: 2316775 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 527560 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999900791 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999900791 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999900791 Country of ref document: EP |